Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Will The Pfizer-Mylan Deal Face Antitrust Hurdles?

Aug 01 2019

• By Brenda Sandburg

WASHINGTON, DC - MAY 4: Federal Trade Commission Headquarters in downtown Washington, DC on May 4, 2015. — Pfizer-Mylan proposed transaction faces FTC scrutiny

Related Content

When It Comes To FTC M&A Review, The Times May Be A Changin'

Jul 18 2019

AbbVie Pounces On Chance To Buy Revenues In $63bn Mega-Deal For Allergan

Jun 25 2019

In Merger Plot Twist, BMS Needs A Buyer For Celgene's Otezla, Raising New Questions

Jun 24 2019

Teva Embarks On New Phase With FTC Clearance Of Allergan Generics

Jul 28 2016

The End Is Nigh For Mylan, But How Different Will The New Company Be?

Jul 31 2019

Upjohn/Mylan: Will "Potential Moderate Growth" Lure Investors?

Jul 29 2019

Love From Shanghai: Upjohn Started Here But Will It Stay Post-Mylan?

Jul 30 2019

Related Companies

Pfizer Inc.

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

Allergan plc

Spark Therapeutics, Inc.

Roche Holding AG

Johnson & Johnson

Amgen, Inc.

Allergan plc

Allergan plc

Barr Pharmaceuticals

AbbVie Inc.

Bristol Myers Squibb Company

Additional Topics

Legal Issues Generic Drugs M & A Policy Regulation BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window